Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARISH N THAKKAR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1053410910
CMS profile
228980
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,224.73

131 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,107.94 128
Education $116.79 3

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARISH N THAKKAR

NPI 1053410910 · CMS profile ID 228980

Allopathic & Osteopathic Physicians / Internal Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053410910?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARISH N THAKKAR, NPI 1053410910, CMS profile ID 228980. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053410910?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HARISH N THAKKAR, NPI 1053410910, CMS profile ID 228980. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053410910?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HARISH N THAKKAR, NPI 1053410910, CMS profile ID 228980, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1053410910?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

131 matching records · $2,224.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 131 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–131 of 131.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $21.2903/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825345947 CMS
GlaxoSmithKline, LLC. $22.6103/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802295207 CMS
DEXCOM, INC. $4.9903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845301441 CMS
Novartis Pharmaceuticals Corporation $9.9503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813310753 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.1903/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850280469 CMS
Amarin Pharma Inc. $11.6003/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815102669 CMS
AstraZeneca Pharmaceuticals LP $14.7003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834318847 CMS
Paratek Pharmaceuticals, Inc. $10.0003/15/2021 Education No dispute reported Delay: No
Change: CHANGED
06/30/2026 813531673 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.0203/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850353009 CMS
DEXCOM, INC. $27.3203/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845301439 CMS
Novo Nordisk Inc $21.1803/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810644601 CMS
Esperion Therapeutics, Inc. $19.6403/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420815 CMS
DEXCOM, INC. $5.7502/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845301437 CMS
Esperion Therapeutics, Inc. $7.5002/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420811 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.8502/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850261309 CMS
Esperion Therapeutics, Inc. $15.3102/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420807 CMS
Novartis Pharmaceuticals Corporation $12.7802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813310749 CMS
Esperion Therapeutics, Inc. $12.9002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420803 CMS
DEXCOM, INC. $8.2402/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845301435 CMS
AstraZeneca Pharmaceuticals LP $17.6502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834352275 CMS
Esperion Therapeutics, Inc. $13.9101/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420799 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.5301/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850255873 CMS
DEXCOM, INC. $14.4201/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845301433 CMS
Novartis Pharmaceuticals Corporation $13.2701/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813310745 CMS
Cumberland Pharmaceuticals, Inc. $63.5801/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854710929 CMS
CeQur Corporation $10.3301/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855401747 CMS
Radius Health, Inc. $14.3101/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830745623 CMS
Novo Nordisk Inc $14.6801/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811450771 CMS
Esperion Therapeutics, Inc. $18.4801/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420795 CMS
Esperion Therapeutics, Inc. $9.5001/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838420791 CMS
Medtronic, Inc. $19.5701/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815575147 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,058.21 143
PY2020 $1,667.40 107
PY2021 $2,224.73 131
PY2022 $2,580.42 148
PY2023 $7,937.16 189
PY2024 $3,823.51 133
PY2025 $1,990.29 102

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,146,565.05 42
PY2024 Principal investigator $616,026.73 43
PY2023 Principal investigator $463,204.19 82
PY2022 Principal investigator $1,479,016.79 65
PY2021 Principal investigator $2,065,396.11 155
PY2020 Principal investigator $352,635.68 22
PY2019 Principal investigator $200,542.29 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,817.63 12/29/2025 Non-covered Recipient Entity
OLYMPUS CLINICAL RESEARCH, LLC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185541904
Principal investigator 1 Currax Pharmaceuticals LLC $452.93 12/24/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716665
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,923.64 12/05/2025 Non-covered Recipient Entity
OLYMPUS CLINICAL RESEARCH, LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185541906
Principal investigator 1 Currax Pharmaceuticals LLC $14,880.00 12/04/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716663
Principal investigator 1 IBSA Institut Biochimique SA $8,463.36 12/03/2025 Non-covered Recipient Entity
WCG CLINICAL, INC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223438979
Principal investigator 1 IBSA Institut Biochimique SA $3,389.44 12/03/2025 Non-covered Recipient Entity
WCG CLINICAL, INC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223439125
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,084.00 12/01/2025 Non-covered Recipient Entity
OLYMPUS CLINICAL RESEARCH, LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185541900
Principal investigator 1 Exeltis, USA Inc. $1,100.00 11/21/2025 Non-covered Recipient Entity
MT OLYMPUS MEDICAL RESEARCH
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females No dispute reported 06/30/2026 1218193336
Principal investigator 1 SANOFI PASTEUR INC. $314,806.35 11/14/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098646
Principal investigator 1 SANOFI PASTEUR INC. $19,763.00 11/14/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098651
Principal investigator 1 Currax Pharmaceuticals LLC $2,960.55 11/13/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716659
Principal investigator 1 Currax Pharmaceuticals LLC $2,741.86 11/13/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716661
Principal investigator 1 SANOFI PASTEUR INC. $14,650.08 11/05/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098633
Principal investigator 1 SANOFI PASTEUR INC. $29,216.74 10/23/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098657
Principal investigator 1 Currax Pharmaceuticals LLC $5,209.01 10/14/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716657
Principal investigator 1 SANOFI PASTEUR INC. $3,662.52 10/10/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098640
Principal investigator 1 Currax Pharmaceuticals LLC $4,375.36 06/24/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716655
Principal investigator 1 SANOFI PASTEUR INC. $216,815.16 06/12/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098628
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,200.00 06/04/2025 Non-covered Recipient Entity
Pharmaseek, LLC (DBA WCG Clinical)
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215505127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,200.00 06/04/2025 Non-covered Recipient Entity
Pharmaseek, LLC (DBA WCG Clinical)
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215505134
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,200.00 06/04/2025 Non-covered Recipient Entity
Pharmaseek, LLC (DBA WCG Clinical)
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215505175
Principal investigator 1 SANOFI PASTEUR INC. $17,288.64 06/02/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098622
Principal investigator 1 Currax Pharmaceuticals LLC $4,735.13 05/28/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716653
Principal investigator 1 ModernaTX, Inc. $13,500.00 05/28/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948940
Principal investigator 1 IBSA Institut Biochimique SA $1,000.00 05/14/2025 Non-covered Recipient Entity
WCG CLINICAL, INC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223439065
Principal investigator 1 SANOFI PASTEUR INC. $52,751.88 04/28/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098575
Principal investigator 1 Currax Pharmaceuticals LLC $2,721.60 04/24/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716651
Principal investigator 1 IBSA Institut Biochimique SA $3,200.00 04/24/2025 Non-covered Recipient Entity
WCG CLINICAL, INC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223438771
Principal investigator 1 IBSA Institut Biochimique SA $75.00 04/24/2025 Non-covered Recipient Entity
WCG CLINICAL, INC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223438773
Principal investigator 1 ModernaTX, Inc. $18,589.05 04/16/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948942
Principal investigator 1 ModernaTX, Inc. $12,324.70 04/16/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948948
Principal investigator 1 ModernaTX, Inc. $11,674.60 04/16/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948950
Principal investigator 1 IBSA Institut Biochimique SA $1,175.04 04/04/2025 Non-covered Recipient Entity
WCG CLINICAL, INC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223438739
Principal investigator 1 IBSA Institut Biochimique SA $1,827.84 04/04/2025 Non-covered Recipient Entity
WCG CLINICAL, INC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223439033
Principal investigator 1 Currax Pharmaceuticals LLC $4,217.40 03/27/2025 Non-covered Recipient Entity
Olympus Clinical Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242716649
Principal investigator 1 ModernaTX, Inc. $4,617.00 03/26/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948938
Principal investigator 1 SANOFI PASTEUR INC. $121,722.90 03/24/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098564
Principal investigator 1 SANOFI PASTEUR INC. $177,320.34 03/11/2025 Non-covered Recipient Entity
Olympus Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226098558
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,512.30 02/28/2025 Non-covered Recipient Entity
OLYMPUS CLINICAL RESEARCH, LLC
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185541902
Principal investigator 1 ModernaTX, Inc. $400.00 02/26/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948944
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/26/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948946
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/26/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252948952